HS
OLMA icon

HighVista Strategies’s Olema Pharmaceuticals OLMA Stock Holding History

HighVista Strategies’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Sell
117,601
-123,888
-51% -$2.76M 0.48% 63
2025
Q4 		$6.04M Sell
241,489
-195,690
-45% -$3.48M 1.55% 18
2025
Q3 		$4.28M Buy
437,179
+158,749
+57% +$953K 1.05% 22
2025
Q2 		$1.19M Buy
278,430
+66,245
+31% +$295K 0.44% 97
2025
Q1 		$798K Hold
212,185
– – 0.31% 117
2024
Q4 		$1.24M Hold
212,185
– – 0.46% 99
2024
Q3 		$2.53M Sell
212,185
-35,695
-14% -$456K 0.87% 33
2024
Q2 		$2.68M Hold
247,880
– – 0.98% 28
2024
Q1 		$2.81M Hold
247,880
– – 1% 29
2023
Q4 		$3.48M Hold
247,880
– – 1.26% 24
2023
Q3 		$3.06M Sell
247,880
-44,396
-15% -$453K 1.42% 17
2023
Q2 		$2.64M Buy
+292,276
New +$1.76M 1.21% 24
2022
Q1 		– Sell
-50,942
Closed -$477K – 94
2021
Q4 		$477K Buy
50,942
+29,943
+143% +$620K 0.38% 65
2021
Q3 		$579K Sell
20,999
-8,123
-28% -$219K 0.38% 69
2021
Q2 		$815K Buy
29,122
+14,667
+101% +$417K 0.58% 40
2021
Q1 		$480K Buy
+14,455
New +$619K 0.36% 72

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

HighVista Strategies's OLMA Position: Q1 2026 in Review

HighVista Strategies reduced its Olema Pharmaceuticals (OLMA) stake by 51% in Q1 2026, selling an estimated $2.76M and leaving 117,601 shares worth $1.75M. The position accounts for 0.48% of the portfolio, ranked #63.

HighVista Strategies first reported a position in OLMA in Q1 2021 and has held it in 16 quarters since. The position peaked at $6.04M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • HighVista Strategies held 117,601 shares of Olema Pharmaceuticals worth $1.75M as of Q1 2026.
  • HighVista Strategies sold 123,888 Olema Pharmaceuticals shares in Q1 2026, an estimated $2.76M.
  • Olema Pharmaceuticals made up 0.48% of HighVista Strategies's portfolio in Q1 2026, its #63 holding.
  • HighVista Strategies first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
  • HighVista Strategies's Olema Pharmaceuticals position peaked at $6.04M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.